Skip to main content

Biotech stocks dominate our list of top charts today. Here are four to watch.

Image placeholder title

1. Exelixis (EXEL) - Get Exelixis Inc. Report

This stock has had a fantastic run in recent months. It's now trading for more than $11, up from less than $4 in March. The stock spiked earlier this month after the company reported second-quarter results that exceeded analyst expectations and revealed information about the launch of its new kidney cancer drug. The stock pulled back from that high, forming a wedge, but broke out of that wedge in recent sessions. On Monday it was up 44 cents, or 4%, to $11.44 on 7.4 million shares, the best volume on an up day in a couple weeks. If it can get through the recent spike high at $11.66, the stock could run to $12.75-$13.00 in the short term.

Image placeholder title

2. Nektar Therapeutics (NKTR) - Get Nektar Therapeutics Report

Nektar looks ready to break out of a bullish flag formation. The biopharmaceutical stock on Monday advanced 57 cents, or 3.3%, to $17.83 on no news, with volume increasing to 785,097 shares traded, the best in two weeks. The move put the stock right up against the declining tops line of the three-week flag. A break above recent highs in the $18.00-$18.10 range could cause the stock to spike to $20 and then maybe even $22.50-$23.00.

Scroll to Continue

TheStreet Recommends

Image placeholder title

3. Progenics Pharmaceuticals (PGNX) - Get Progenics Pharmaceuticals, Inc. Report

This stock is consolidating within a steep upward channel off its June low at $4. The biopharma stock looks ready to break out of the two-week consolidation. On Monday it rose 15 cents, or 2.2%, to $6.97 on volume of 1 million shares. Watch for a follow-through above recent highs in the $7.05 area, beyond which the stock could run to the $7.75-$8.25 range in the near term. It could go as high as $11 on an intermediate basis.

Image placeholder title

4. Puma Biotechnology (PBYI) - Get Puma Biotechnology Inc Report

Puma is in a strong uptrend, having formed a head-and-shoulders bottom off its May low of less than $20. The stock had an excellent day on Monday, rising $4.56, or 9%, to $54.65 on 1.2 million shares. The move came on news that the European Medicines Agency will begin formally reviewing its breast cancer treatment. The stock reached a key resistance area near its intraday high at $55.43. A punch through $55.50 could get the stock up near $68, which is the next target.

See Harry's Boxer's video chart analysis on these stocks.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.